Clinical trials: Substance Abuse Detection
- Condition Substance Abuse Detection
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Healthy Volunteers
Bioavailability Study of Fexofenadine HCl New Formulation Tablet
The purpose of the study is to assess the relative bioavailability of a new galenic form of fexofenadine HCl new formulation tablet (test drug) taken with or without water compared to fexofenadine HCl film-coated tablets…
- Trial name
- NCT06284902
- Testing
- Fexofenadine HCl Coated tablet, Fexofenadine HCl New Formulation Tablet
- Where
- Canada
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Opella Healthcare Group SAS, a Sanofi Company
Bioequivalence
Study in Healthy Male Subjects to Demonstrate Bioequivalence of 1600 μg Selexipag Administered as Eight Tablets of 200 μg or as Single Tablet of 1600 μg
The primary aim of this study is to demonstrate bioequivalence in the rate and extent of absorption between 1600 μg selexipag test drug (administered orally as film-coated tablets of 1600 μg, twice a day (b.i.d.) and 1600 μg…
- Trial name
- NCT02206295
- Testing
- selexipag
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Actelion
Nebulizers and Vaporizers
Explorative Clinical Investigation to Investigate the Ability of PreciseInhale to Direct Regional Lung Targeting and Reduce the Degree of Throat Deposition and Subsequent Gastrointestinal Absorption in Healthy Volunteers After Inhalation of Test Drug Substances Via the PreciseInhale System
This is a single site, open label, 4-inhalation sessions, explorative clinical investigation to investigate the ability of PreciseInhale to direct regional lung targeting and reduce the degree of throat deposition and subsequent…
- Trial name
- NCT04946630
- Testing
- PreciseInhale, Seretide Evohaler forte
- Where
- Sweden
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Inhalation Sciences Sweden AB
Cannabis Intoxication
Cannabis Impairment Detection Device Study
The goal of this study is to develop a cannabis impairment detection device in adult cannabis users. The main question[s] it aims to answer are: Is the investigational device accurate and reliable at detecting cannabis…
- Trial name
- NCT07122349
- Testing
- Cannabis Impairment Test
- Where
- Canada
- Volunteers
- 362 people, healthy volunteers welcome
- Sponsor
- Gaize
Driving Under the Influence, Marijuana Intoxication
Cannabis Impairment Detection Application (CIDA)
Subjects will participate in a 4-visit study protocol in which they will be asked to complete a set of computerized tasks and a 45-minute simulated drive in a driving simulator.
- Conditions
- Driving Under the Influence, Marijuana Intoxication, Alcohol Intoxication
- Trial name
- CIDA (NCT04230460)
- Testing
- Cannabis (High% THC) (Inhaled), Cannabis (Very High% THC) (Inhaled), Alcohol (oral)
- Where
- United States
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Advanced Brain Monitoring, Inc.
Target Drug-related Adverse Events
Standard of Care Versus Urine Testing With Selective PHarmacogenomics for Effective Drug and Dosing REgimens
The purpose of this study is to determine whether the addition of selective pharmacogenomic (PGx) testing as determined by Urine Drug Testing (UDT) adds a clinical benefit as evidenced by a reduction in Target Drug-related…
- Trial name
- SPHERE (NCT02625155)
- Testing
- Urine diagnostic testing as SOC, drug regimen changes per SOC, Urine diagnostic testing with selective PGx testing, drug regimen changes based on PGx test results
- Where
- United States
- Volunteers
- 14,000 people, healthy volunteers welcome
- Sponsor
- InSource Diagnostics
Breast Neoplasms, Lung Neoplasms
Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis
DiaTech is a private company performing patient specific cancer chemosensitivity testing for patients and physicians. DiaTech Oncology is doing this clinical study to see if an experimental new technology called the microculture…
- Conditions
- Breast Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Sarcoma, Soft Tissue
- Trial name
- NCT00243685
- Testing
- Laboratory Assay, Mick Assay
- Where
- 3 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Pierian Biosciences
Gout
Lesinurad/Allopurinol 200/300 Fixed-Dose Combination (FDC) Tablets Bioequivalence.
To assess the bioequivalence between lesinurad/allopurinol 200/300 FDC tablets and coadministered lesinurad and allopurinol tablets in the fasted state based on the pharmacokinetic (PK) evaluation of lesinurad and allopurinol in…
- Trial name
- NCT03272425
- Testing
- lesinurad/allopurinol 200/300 FDC tablets, lesinurad 200 mg, allopurinol 300 mg
- Where
- Brazil
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Ardea Biosciences, Inc.